Rhesus monkey alpha7 nicotinic acetylcholine receptors: comparisons to human alpha7 receptors expressed in Xenopus oocytes.
An alpha7 nicotinic acetylcholine receptor sequence was cloned from Rhesus monkey (Macaca mulatta). This clone differs from the mature human alpha7 nicotinic acetylcholine receptor in only four amino acids, two of which are in the extracellular domain. The monkey alpha7 nicotinic receptor was characterized in regard to its functional responses to acetylcholine, choline, cytisine, and the experimental alpha7-selective agonists 4OH-GTS-21, TC-1698, and AR-R17779. For all of these agonists, the EC(50) for activation of monkey receptors was uniformly higher than for human receptors. In contrast, the potencies of mecamylamine and MLA for inhibiting monkey and human alpha7 were comparable. Acetylcholine and 4OH-GTS-21 were used to probe the significance of the single point differences in the extracellular domain. Mutants with the two different amino acids in the extracellular domain of the monkey receptor changed to the corresponding sequence of the human receptor had responses to these agonists that were not significantly different in EC(50) from wild-type human alpha7 nicotinic receptors. Monkey alpha7 nicotinic receptors have a serine at residue 171, while the human receptors have an asparagine at this site. Monkey S171N mutants were more like human alpha7 nicotinic receptors, while mutations at the other site (K186R) had relatively little effect. These experiments point toward the basic utility of the monkey receptor as a model for the human alpha7 nicotinic receptor, albeit with the caveat that these receptors will vary in their agonist concentration dependency. They also point to the potential importance of a newly identified sequence element for modeling the specific amino acids involved with receptor activation.
Papke
Roger L
RL
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, 32610, USA. rlpapke@ufl.edu
McCormack
Thomas J
TJ
Jack
Brian A
BA
Wang
Daguang
D
Bugaj-Gaweda
Bozena
B
Schiff
Hillary C
HC
Buhr
Joshua D
JD
Waber
Amanda J
AJ
Stokes
Clare
C
D000109:Acetylcholine / Q000494:pharmacology; D000157:Aconitine / Q000031:analogs & derivatives / Q000494:pharmacology; D000465:Algorithms; D000470:Alkaloids / Q000494:pharmacology; D000595:Amino Acid Sequence; D000691:Anabasine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001392:Azocines / Q000494:pharmacology; D001643:Bridged Bicyclo Compounds; D002794:Choline / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008253:Macaca mulatta; D008464:Mecamylamine / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects; D008845:Microinjections; D008969:Molecular Sequence Data; D009154:Mutation; D018733:Nicotinic Antagonists / Q000494:pharmacology; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D011725:Pyridines; D011807:Quinolizines / Q000494:pharmacology; D018075:RNA, Complementary / Q000008:administration & dosage / Q000235:genetics; D011978:Receptors, Nicotinic / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D040681:Structural Homology, Protein; D014982:Xenopus laevis; D064569:alpha7 Nicotinic Acetylcholine Receptor; D000093843:Quinolizidine Alkaloids
D000109:Acetylcholine; D000157:Aconitine; D000470:Alkaloids; D000691:Anabasine; D001392:Azocines; D001643:Bridged Bicyclo Compounds; D002794:Choline; D008464:Mecamylamine; D018733:Nicotinic Antagonists; D011725:Pyridines; D011807:Quinolizines; D018075:RNA, Complementary; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; C484276:2-(3-pyridyl)-1-azabicyclo(3.2.2)nonane; C116666:3-(4-hydroxy-2-methoxybenzylidene)anabaseine; C579167:Chrna7 protein, human; C054634:methyllycaconitine; C004712:cytisine; D000093843:Quinolizidine Alkaloids